can you take a glp 1 without gallbladder GLP-1 Gallbladder: Safety, Biomarkers & Provider Guidance – PlexusDx GLP-1 Without Gallbladder: Safety, Biomarkers
Description
This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Set yourself up for success with this expert advice.
However, the drugs alterations in gut motility may account for many of their commonly reported adverse effects including nausea, vomiting, early satiety, dyspepsia, and bowel habit changes
Welcome to the final video in my semaglutide journey series
All health begins in the gut
